Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers
Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer
Key insights from head and neck research at ASCO 2025
Transforming cancer care in India: The Access Cancer Care Initiative
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC
Independent clones in CLL show oligoclonality and early evolution patterns
Breast cancer survivorship
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results
Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia
Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM
Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies